Stock Track | Alkermes PLC Soars 5.03% Intraday on Strong Q1 Earnings Beat and Phase 3 Clinical Program Initiation

Stock Track

May 06

Alkermes PLC's stock surged 5.03% during Tuesday's intraday trading session following the release of its first-quarter 2026 financial results, which significantly exceeded analyst expectations.

The biopharmaceutical company reported a quarterly loss of $0.40 per share, which was notably better than the consensus estimate of a $0.57 loss. More impressively, revenue jumped 28.2% year-over-year to $392.91 million, surpassing the expected $359.85 million. The company also reiterated its full-year 2026 revenue guidance range of $1.73 billion to $1.84 billion, which aligns with market expectations.

Additionally, Alkermes announced the initiation of its Alixorexton Brilliance Phase 3 narcolepsy clinical program in the first quarter of 2026, marking progress in its neuroscience pipeline. This combination of better-than-expected financial performance and pipeline advancement appears to have driven investor optimism, resulting in the stock's significant price increase.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1154009468"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1154009468\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1154009468?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 00:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154009468","market":"nz","top_or_hot":-1,"title":"Stock Track | Alkermes PLC Soars 5.03% Intraday on Strong Q1 Earnings Beat and Phase 3 Clinical Program Initiation","media":"Stock Track","content":"<p>Alkermes PLC's stock surged 5.03% during Tuesday's intraday trading session following the release of its first-quarter 2026 financial results, which significantly exceeded analyst expectations.</p><p>The biopharmaceutical company reported a quarterly loss of $0.40 per share, which was notably better than the consensus estimate of a $0.57 loss. More impressively, revenue jumped 28.2% year-over-year to $392.91 million, surpassing the expected $359.85 million. The company also reiterated its full-year 2026 revenue guidance range of $1.73 billion to $1.84 billion, which aligns with market expectations.</p><p>Additionally, Alkermes announced the initiation of its Alixorexton Brilliance Phase 3 narcolepsy clinical program in the first quarter of 2026, marking progress in its neuroscience pipeline. This combination of better-than-expected financial performance and pipeline advancement appears to have driven investor optimism, resulting in the stock's significant price increase.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Alkermes PLC Soars 5.03% Intraday on Strong Q1 Earnings Beat and Phase 3 Clinical Program Initiation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Alkermes PLC Soars 5.03% Intraday on Strong Q1 Earnings Beat and Phase 3 Clinical Program Initiation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-06 00:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Alkermes PLC's stock surged 5.03% during Tuesday's intraday trading session following the release of its first-quarter 2026 financial results, which significantly exceeded analyst expectations.</p><p>The biopharmaceutical company reported a quarterly loss of $0.40 per share, which was notably better than the consensus estimate of a $0.57 loss. More impressively, revenue jumped 28.2% year-over-year to $392.91 million, surpassing the expected $359.85 million. The company also reiterated its full-year 2026 revenue guidance range of $1.73 billion to $1.84 billion, which aligns with market expectations.</p><p>Additionally, Alkermes announced the initiation of its Alixorexton Brilliance Phase 3 narcolepsy clinical program in the first quarter of 2026, marking progress in its neuroscience pipeline. This combination of better-than-expected financial performance and pipeline advancement appears to have driven investor optimism, resulting in the stock's significant price increase.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALKS","symbol_name":"阿尔凯默斯","start_time":0,"source_url":"","article_id":"1154009468","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154009468","pubTimestamp":1777997078,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Alkermes PLC's stock surged 5.03% during Tuesday's intraday trading session following the release of its first-quarter 2026 financial results, which significantly exceeded analyst expectations.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALKS":"阿尔凯默斯"},"translate_title":"个股追踪|Alkermes PLC盘中飙升5.03%，因Q1盈利强劲且启动3期临床项目","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALKS":1},"content_text":"Alkermes PLC's stock surged 5.03% during Tuesday's intraday trading session following the release of its first-quarter 2026 financial results, which significantly exceeded analyst expectations.The biopharmaceutical company reported a quarterly loss of $0.40 per share, which was notably better than the consensus estimate of a $0.57 loss. More impressively, revenue jumped 28.2% year-over-year to $392.91 million, surpassing the expected $359.85 million. The company also reiterated its full-year 2026 revenue guidance range of $1.73 billion to $1.84 billion, which aligns with market expectations.Additionally, Alkermes announced the initiation of its Alixorexton Brilliance Phase 3 narcolepsy clinical program in the first quarter of 2026, marking progress in its neuroscience pipeline. This combination of better-than-expected financial performance and pipeline advancement appears to have driven investor optimism, resulting in the stock's significant price increase.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}